-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anaplastic large cell lymphoma (ALCL) is a T-cell/Zero cell line (NHL) of CD30+ invasive non-Hodgkin lymphoma (NHL), which accounts for 2%
of all NHL in adults.
Therefore, a research team used the observational database of the International Center for Blood and Bone Marrow Transplantation Research (CIBMTR) to assess the prognosis
of allogeneic-HCT in patients with ALCL.
Figure 1: Allogeneic hematopoietic cell transplant results
for anaplastic large-cell lymphoma.
Figure 2: Effect
of disease status on transplant outcomes.
About multivariate regression analysis of African American ethnicity (risk ratio [HR] 2.
Overall, these data suggest that allo-HCT can achieve lasting disease control
in a significant proportion of patients with R/R ALCL.
Original Source:
Furqan, F, Ahn, KW, Chen, Y, Kaur, M, Abutalib, SA, Ahmed, N, et al.